September 10, 2019 Cost Estimate As ordered reported by the House Committee on Ways and Means on June 26, 2019 View Document98.49 KB Summary The bill would Modify the rules for coordinating coverage between Medicare and TRICARE, the military health benefits plan Make the DNA specimen provenance assay (DSPA) for prostate cancer screening a Medicare-covered service Make funding available to improve fee-for-service benefits in Medicare Prohibit Medicare payment adjustments for some durable medical equipment (DME) Change supervision requirements for some outpatient services Estimated budgetary effects would primarily stem from Changing the rules for Medicare and TRICARE coordination Adding Medicare coverage for the DSPA Excluding Medicare payment adjustments for some DME Spending of funds deposited into the Medicare Improvement Fund Areas of significant uncertainty include Projecting the number of military retirees who would forgo enrollment in Medicare Part B Anticipating trends in prostate cancer testing and treatment Data and Supplemental Information Table Appearing in the Estimate Legislative Information Available From Congress.gov
The bill would Modify the rules for coordinating coverage between Medicare and TRICARE, the military health benefits plan Make the DNA specimen provenance assay (DSPA) for prostate cancer screening a Medicare-covered service Make funding available to improve fee-for-service benefits in Medicare Prohibit Medicare payment adjustments for some durable medical equipment (DME) Change supervision requirements for some outpatient services Estimated budgetary effects would primarily stem from Changing the rules for Medicare and TRICARE coordination Adding Medicare coverage for the DSPA Excluding Medicare payment adjustments for some DME Spending of funds deposited into the Medicare Improvement Fund Areas of significant uncertainty include Projecting the number of military retirees who would forgo enrollment in Medicare Part B Anticipating trends in prostate cancer testing and treatment